Engflag

Topalgic LP

Quick links to important sections

Topalgic LP

Topalgic LP_EN

Method of action: Analgesic, Analgesic (Opioid), Analgetic, Opioid, Vitamins

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Topalgic LP

WHAT IS TOPALGIC LP?

Property Description
Active ingredient Tramadol Hydrochloride
Form Extended-release (LP) tablets
Pharmacological class Centrally acting synthetic opioid analgesic
Common Use Pain relief
Origin Synthetic

What Type of Medicine is Topalgic LP (Tramadol)?

Topalgic LP is a prescription medicine whose active component is Tramadol Hydrochloride, which is formally classified as a centrally acting synthetic opioid analgesic. This classification confirms its action is primarily focused on the central nervous system—the brain and spinal cord—to modulate the perception and transmission of pain signals. As a synthetic compound, Tramadol is chemically manufactured, differentiating it from substances derived directly from natural plant sources. This substance is clinically recognized for its efficacy when managing pain that is not adequately controlled by non-opioid medications.

Composition and the Extended-Release (LP) Form

The medication is a single product, containing only the active component Tramadol Hydrochloride. The LP in the name signifies a Long-Period or Extended-Release formulation, indicating the tablets are designed for a prolonged effect. This oral solid dosage form is engineered using specialized pharmaceutical excipients to control the dissolution and absorption rate of the active ingredient, ensuring it is released slowly and consistently over many hours. The sustained action profile of the LP formulation is a key difference from standard immediate-release forms, making it suitable when a consistent level of pain management is needed throughout the day.

General Purpose of this Dual-Action Analgesic

The general purpose of Topalgic LP is to provide analgesic potency for effective pain relief. This benefit is achieved through the drug's distinctive dual-action mechanism, a multimodal approach to managing pain. The medicine works by both engaging specific opioid receptors and modulating the effects of two key neurotransmitters, Serotonin and Norepinephrine, which activate the body's natural descending pain inhibitory pathways. This combination is pharmacologically supported for providing pain management through two synergistic routes, offering continuous pain relief over the extended period facilitated by the LP design.

Regulatory References

  1. Serotonin and Norepinephrine in Pain Pathways

What side effects are possible with Topalgic LP?

Possible Side Effects and Safety Information

The safety profile of Topalgic LP (Tramadol Hydrochloride extended-release) is based on official classifications of adverse reactions by governmental regulatory authorities.

Officially Documented Adverse Reactions

Adverse reactions are formally categorized by their frequency, as observed in clinical data and post-marketing surveillance:

Classification Examples of Officially Listed Adverse Reactions
Very Common (Affects 1 in 10) Nausea, Dizziness
Common (Affects 1 in 100) Headache, Somnolence (Drowsiness), Constipation, Vomiting, Dry mouth, Hyperhidrosis (Sweating), Fatigue
Rare (Affects 1 in 10,000) Respiratory depression, Convulsions (Seizures), Anaphylaxis, Confusion, Hallucinations

These effects are typically grouped by the affected System-Organ-Class, including the Nervous System, Gastrointestinal System, and Psychiatric systems.

Serious Safety Considerations

Official labeling highlights several serious adverse reactions, which may be life-threatening. These include Life-Threatening Respiratory Depression, the risk of Opioid Addiction, Abuse, and Misuse, and the potential for Serotonin Syndrome (especially when used with other serotonergic medicines) or Seizures. The risk of serious respiratory depression is highest when initiating therapy or following a dose increase.

Population and Use Restrictions

Specific safety considerations exist for certain populations. The medicine is contraindicated in children younger than 12 years. Use is restricted in patients with severe renal or hepatic impairment. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome in the newborn, as documented in regulatory warnings. The official safety constraints also include the risk of profound sedation or respiratory depression with concomitant use of other Central Nervous System depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the overdose profile for Topalgic LP (Tramadol Hydrochloride) based on severe, life-threatening manifestations, requiring specific emergency action.

Documented Clinical Manifestations

System Officially Documented Symptoms and Signs
Central Nervous System Extreme drowsiness, loss of consciousness, coma, convulsions or seizures, and miosis (pinpoint pupils).
Respiratory System Respiratory depression (slow, shallow, or difficult breathing), long pauses between breaths, respiratory arrest, and fatal outcomes.
Cardiovascular System Cardiovascular collapse and severe arrhythmias.

Required Emergency Actions

Any suspected overdose or the presence of these symptoms mandates seeking immediate medical attention and contacting emergency services immediately. Urgent medical care is specifically required for signs such as unresponsiveness or slowed breathing.

Antidote and Supportive Care: The reversal agent naloxone is indicated for managing respiratory depression; however, official labeling states it may only partially reverse the effects and can increase the risk of seizure. Management focuses on symptomatic and supportive treatment, prioritizing adequate ventilation and close monitoring.

Population Note: The accidental ingestion of even a single dose of this extended-release formulation has been documented as a risk for fatal overdose in children.

Therapeutic Uses of Topalgic LP

Quick Facts: Uses of Topalgic LP

  • Targeted Symptom: Helps manage moderate to severe pain in adults and adolescents over 12 years of age.
  • Treatment Goal: Intended for pain that requires a continuous, around-the-clock opioid analgesic for an extended period of time.
  • Therapeutic Focus: Assists in providing relief when non-opioid pain treatments are inadequate.

Topalgic LP, which contains tramadol, is approved for the management of pain that ranges from moderate to severe. This medication is intended for use in patients, including adults and adolescents older than 12 years, who require an analgesic administered on a daily, continuous basis over an extended timeframe.

The therapeutic objective of Topalgic LP is to help provide sustained pain relief when other alternative pain management strategies have not been effective or are not tolerated. The formulation is designed to release the active component over a longer duration, supporting management of ongoing discomfort. Its use is focused strictly on pain that is severe enough to necessitate this level of treatment.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Topalgic LP — official regulatory information

Topalgic LP (Tramadol Extended-Release) is authorized for use in adults and adolescents 12 years of age and older who require daily, continuous opioid treatment. The eligibility profile is structured by numerous contraindications that absolutely prohibit its use.

Populations for whom use is contraindicated

  • Age and Clinical Status: Children younger than 12 years; adolescents under 18 years following tonsillectomy or adenoidectomy; patients with uncontrolled epilepsy.
  • Acute Clinical State: Patients with severe respiratory depression or acute, severe bronchial asthma; known gastrointestinal obstruction (e.g., paralytic ileus); or acute intoxication by alcohol, sedatives, or other centrally acting drugs.
  • Concurrent Drug Use: Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have used them within the last 14 days.

Populations with Restricted or Not Recommended Use

  • Organ Function: Use is not recommended in patients with severe hepatic impairment or severe renal impairment.
  • Reproductive Status: Pregnancy use is not recommended due to the risk of Neonatal Opioid Withdrawal Syndrome. Chronic use during breastfeeding is contraindicated.
  • Age and Comorbidity: Use requires greater caution in patients over 75 years of age and adolescents (12–18 years) with existing risk factors for serious breathing problems.

What should I know about interactions with other medicines?

Official Interactions with Other Medicines and Products

The interaction profile for Topalgic LP (Tramadol) is defined by official government documents, focusing on pharmacodynamic reinforcement and metabolic alteration.

Category Interaction Pattern (Regulatory Basis)
Formal Contraindication Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited; a 14-day separation period is mandatory before and after use. The drug is also contraindicated in cases of acute intoxication with alcohol or other CNS depressants.
CNS & Serotonin Risk Concomitant use with CNS Depressants (e.g., alcohol, hypnotics, other opioids) carries a documented risk of additive effects, including profound sedation and respiratory depression. Use with Serotonergic Agents (e.g., SSRIs, SNRIs, Triptans) increases the risk of Serotonin Syndrome and lowered seizure threshold.
Metabolic Modification (PK) CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine) and CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin) may increase the exposure of the parent drug. Conversely, strong CYP3A4 Inducers like Carbamazepine significantly decrease Tramadol exposure, potentially reducing its analgesic effect.
Other Restrictions Caution is required with Coumarin Derivatives (e.g., Warfarin) due to reports of altered International Normalized Ratio (INR). Patients with hepatic or renal impairment may experience a magnified effect of pharmacokinetic interactions due to delayed clearance.

These patterns dictate the mandatory restrictions and avoidances specified in regulatory labeling. The prohibitions center on managing the severe risks associated with additive CNS effects and metabolic changes.

Mechanism of Action

Topalgic LP operates through a dual, centrally-mediated mechanism involving the modulation of nociceptive signal propagation within the Central Nervous System (CNS). The primary pathway involves the active metabolite, O-desmethyltramadol (M1), acting as a full agonist at the mu-opioid receptor (mu-OR). This interaction initiates a molecular cascade that leads to the hyperpolarization of specific neurons, resulting in a reduction in neuronal excitability and the capacity for signal transmission.

The second mechanism involves the parent compound inhibiting the reuptake of the neurotransmitters Norepinephrine (NE) and Serotonin (5-HT) via their respective transporters. This action increases monoamine availability, which enhances the Descending Pain Inhibitory Pathways (DPIS), resulting in the physiological suppression of signal propagation, primarily in the spinal cord. The full mechanistic potential of the mu-OR component is genetically constrained by the individual activity of the CYP2D6 enzyme, required for the conversion to M1.

Dosage and Administration Information

How to Use Topalgic LP

Topalgic LP, which contains Tramadol Hydrochloride, is an extended-release formulation intended for continuous, around-the-clock pain management. The administration of this medicine is guided by established protocols, focusing on the approved dosage schedule and administration conditions.

Official Administration Guidelines

Parameter Instruction Details
Route of administration The approved route for this specific LP formulation is oral (by mouth).
Dosing schedule For opioid-naïve adults, the typical starting dose is 100 mg once daily. Doses may be adjusted in increments of 100 mg, but no more frequently than every five days. The maximum recommended daily dose for this formulation is 300 mg per day.
Frequency pattern The medication is intended for a once daily schedule for continuous use and is not indicated for 'as needed' relief.
Physical Handling The tablets must be swallowed whole with liquid and must not be split, chewed, crushed, or dissolved. Altering the tablet integrity compromises the extended-release mechanism.
Food Relation Topalgic LP may be taken with or without food.

Population-Specific Rules

Specific dosage constraints apply to certain patient populations. The extended-release formulation is not recommended for patients with severe hepatic or renal impairment due to reduced drug clearance. It is also contraindicated for use in children under 12 years of age. When therapy is to be discontinued, the dose should be tapered gradually to follow standardized usage guidelines.

These administration guidelines ensure the medicine is used within the standardized protocol.

Recent Clinical Evidence

Recent Clinical Evidence

Summary of Core Research

Studies investigated the compound in the context of various chronic pain conditions, including osteoarthritis, chronic low back pain, and fibromyalgia. The research examined outcomes related to joint mobility and pain scores using standardized rating scales.

The clinical trials involved adult participants receiving Topalgic LP to investigate differences in measured outcomes related to pain and inflammatory markers over periods typically ranging from 8 to 16 weeks.

Key Findings from Clinical Trials

Focus on Evidence of Difference

  • Pain Reduction: Systematic reviews and meta-analyses of randomized, placebo-controlled trials explored whether Topalgic LP was associated with a reduction in chronic pain scores. Although a statistically significant difference was observed compared to placebo, the size of the effect was reported to be small, in some cases falling below the threshold for a clinically meaningful improvement.
  • Combination Investigation: Research explored whether the combination of the compound with standard therapies yielded different clinical measurements, such as assessments of rescue medication requirements or changes in disease activity scores, when compared to standard therapy alone.
  • Onset of Observed Differences: In clinical trials, researchers monitored the onset of measured differences. One study investigated whether changes in symptom severity were observed during the early period following administration of the prolonged-release formulation.

Focus on Safety and Tolerability

  • Adverse Event Monitoring: Safety assessments in the clinical development program included systematic collection of adverse events (AEs). The most frequently reported AEs included nausea, dizziness, and constipation.
  • Risk Profile: Analysis of pooled trial data found that Topalgic LP was associated with an increased risk of both non-serious and serious adverse events compared to placebo. Serious adverse events were primarily related to cardiac events and newly diagnosed cancers, though the short duration of the trials limited the certainty of a direct causal link to the latter.
  • Research Population: Studies investigated a range of doses to characterize dose-related differences in measured outcomes. The research population in these trials was generally limited to individuals reporting mild to moderate symptoms. Long-term follow-up research is underway to collect data on outcomes and safety beyond the primary trial duration.

Key Studies & References

  1. Pharmacokinetic and Pharmacodynamic Interaction Study of Tapentadol Extended Release and Conventional Analgesics in Healthy Volunteers

How should Topalgic LP be stored and disposed of?

How to Store and Dispose of Topalgic LP?

The storage and disposal of Topalgic LP (Tramadol Hydrochloride) must adhere to official regulatory requirements to ensure stability and safety.

Storage Conditions

Topalgic LP must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C and 30 C. The medication must be kept in a tight container and stored strictly out of the sight and reach of children.

Disposal Instructions

As an opioid, disposal must follow a specific protocol. The preferred method for discarding unused or expired tablets is through drug take-back programs sponsored by local authorities or the DEA. If a take-back option is unavailable, the product must be mixed with an unpalatable substance (e.g., dirt, coffee grounds) and sealed in a container before being placed in the household trash, as mandated by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Topalgic LP found in:

A-Z Index: